Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 486 clinical trials
  • 0 views
  • 25 Jan, 2023
  • 1 location
  • 0 views
  • 28 Apr, 2023
  • 1 location
  • 0 views
  • 29 May, 2023
  • 1 location
Report-Trial 01  

Test Comment here

  • 0 views
  • 15 May, 2023
  • 1 location
  • 0 views
  • 02 Aug, 2023
  • 2 locations
Additional Prescreener Triual01  

Additional Prescreener Triual01

  • 0 views
  • 10 Aug, 2023
  • 1 location
Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata (APACCO) updated  

Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a clinical picture changes to a decrease of all signs of inflammation.Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option.In this study, treatment with …

  • 0 views
  • 14 Mar, 2022
  • 4 locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

  • 0 views
  • 14 Mar, 2022
  • 2 locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI test  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

Accepts healthy volunteers
  • 0 views
  • 14 Mar, 2022
  • 2 locations
Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates (ACBMNC)  

Pre-clinical animal studies provide robust evidence regarding the beneficial effect of stem cells for intestinal disease. This single-center, randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing NEC in preterm neonates,and influence on growth and development.

  • 0 views
  • 14 Mar, 2022
  • 1 location